Table 3.

Number and proportion of cases with serious comorbidities and complications in each DRG.

ADRG	DRG	Before implementation		After implementation		Increase	χ2	P
		Number of cases	Proportion	Number of cases	Proportion
ED1	ED11	151	44.41	115	52.04	7.62	15.891	0.000
	ED13	166	48.82	75	33.94	−14.89
	ED15	23	6.76	31	14.03	7.26
ER1	ER11	174	50.88	98	60.49	9.62	4.092	0.043
	ER15	168	49.12	64	39.51	−9.62
ES1	ES11	194	29.94	141	36.72	6.78	7.004	0.030
	ES13	342	52.78	171	44.53	−8.25
	ES15	112	17.28	72	18.75	1.47
ET1	ET11	34	36.96	60	63.16	26.20	12.835	0.000
	ET15	58	63.04	35	36.84	−26.20
FM3	FM31	405	19.36	339	22.54	3.18	5.394	0.020
	FM35	1,687	80.64	1165	77.46	−3.18
FW1	FW11	172	37.97	66	47.14	9.17	11.285	0.004
	FW13	257	56.73	59	42.14	−14.59
	FW15	24	5.30	15	10.71	5.42
LV1	LV11	175	29.86	148	31.69	1.83	15.759	0.000
	LV13	388	66.21	274	58.67	−7.54
	LV15	23	3.92	45	9.64	5.71
QS4	QS41	45	39.47	60	50.85	11.37	6.242	0.044
	QS43	55	48.25	38	32.20	−16.04
	QS45	14	12.28	20	16.95	4.67
RW2	RW21	629	27.19	524	32.91	5.72	14.880	0.001
	RW23	1,125	48.64	709	44.54	−4.10
	RW25	559	24.17	359	22.55	−1.62
SR1	SR11	189	49.22	381	57.55	8.33	44.936	<0.0001
	SR13	88	22.92	204	30.82	7.90
	SR15	107	27.86	77	11.63	−16.23